Sofosbuvir

CHEMBL1259059 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

529.5 g/mol

LogP

1.0

Phase

4

A cornerstone of modern hepatitis C treatment, this once-daily antiviral blocks a key enzyme the hepatitis C virus needs to copy itself. When combined with other antivirals, it achieves cure rates above 95% in most patients after just 8 to 12 weeks of treatment, with minimal side effects.

الوزن الجزيئي

529,5000 g/mol

LogP

1,00

TPSA

153,00 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Hypertension HIV/AIDS Hepatitis C Heart Failure Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1

InChI

InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1

Molecular Formula

C22H29FN3O9P

HBD / HBA

3 / 11

الروابط القابلة للدوران

11

الذرات الثقيلة

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A cornerstone of modern hepatitis C treatment, this once-daily antiviral blocks a key enzyme the hepatitis C virus needs to copy itself. When combined with other antivirals, it achieves cure rates above 95% in most patients after just 8 to 12 weeks of treatment, with minimal side effects.

Yes, Sofosbuvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1259059. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 45375808. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Sofosbuvir على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C22H29FN3O9P
المرادفات: 8

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.